Search
DaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.
Enzacamene
go.drugbank.com/drugs/DB11219ApprovedWhile its effects on the human reproductive system as an endocrine disruptor are being investigated, its use in over-the-counter and cosmetic products is approved by Health Canada. … It is used in cosmetic products such as sunscreen to provide skin protection against UV rays.
Mixtures: Bain De Soleil Protection Lotion SPF 15Isotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigational[L6574] Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. … [L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Synonyms: (7E,9E,11E,13Z)-retinoic acidFerric pyrophosphate citrate
go.drugbank.com/drugs/DB13995ApprovedThe ferric ion is strongly complexed by pyrophosphate and citrate.[A31979] FPC is categorized in Japan as a second class OTC drug. … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.
Nevirapine
go.drugbank.com/drugs/DB00238ApprovedInvestigationalStructurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Synonyms: 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-oneCategories: Antivirals used in combination for the treatment of HIV infectionsFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalIt was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label]. … Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
Categories: Peripheral Opioid Receptor AntagonistsLeuprolide
go.drugbank.com/drugs/DB00007ApprovedInvestigational[A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. … Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsProducts: TOZ ICEREN SIRINGA VE COZUCU ICEREN SIRINGA, 1 ADET, TOZ ICEREN SIRINGA VE COZUCU ICEREN SIRINGA, 1 ADET